Company Overview of Taisho Pharmaceutical Co., Ltd.
Taisho Pharmaceutical Co., Ltd. manufactures and sells over-the-counter (OTC) medicines and health-related products. The company offers its products in the areas of CNS, diabetes, immunology/allergy, and infectious diseases; and provides self-medication products, such as Rx-to-OTC switch drugs, eye drops, cold remedy medication products, gastrointestinal medication products, energy drinks, hair re-growth treatment medication products, and foods for specified health use. It also provides prescription pharmaceutical products, such as macrolide antibiotics, injectable antibiotics, peripheral vasodilators, nonsteroidal anti-inflammatory drugs, and infection and inflammation/immune-related produc...
Founded in 2011
Key Executives for Taisho Pharmaceutical Co., Ltd.
President and Representative Director
Executive Vice President and Director
Senior Executive Officer and Director
Corporate Adviser and Director
Compensation as of Fiscal Year 2015.
Taisho Pharmaceutical Co., Ltd. Key Developments
Taisho Pharmaceutical Co., Ltd. Presents at 13th Annual BIO Asia International Conference 2016, Mar-15-2016
Mar 11 16
Taisho Pharmaceutical Co., Ltd. Presents at 13th Annual BIO Asia International Conference 2016, Mar-15-2016 . Venue: Grand Hyatt, Tokyo, Japan.
Polyphor and Taisho Pharmaceutical Enter into Research Collaboration on Novel Drug Candidates
Sep 17 15
Polyphor Ltd. announced the signing of a research collaboration agreement with Taisho Pharmaceutical Co., Ltd. The parties will collaborate on the identification of novel drug candidates based on Polyphor's proprietary macrocycle platform.
Taisho Pharmaceutical Co., Ltd. Announces Results from Phase III Osteoarthritis Trials
Jul 30 15
Taisho Pharmaceutical Co., Ltd. has announced results from two Phase III clinical trials with the anti-inflammatory analgesic patch formulation containing S-flurbiprofen, or TT-063, in patients with osteoarthritis. The clinical trials investigated the efficacy of applying TT-063 for two weeks, targeting 633 patients with osteoarthritis of the knee joint. The patients were divided into a group of patients to whom TT-063 was administered, and a group of patients to whom a flurbiprofen gel patch (FP) was administered as a control drug. The trials compared the two groups. The primary endpoint of the study was the change in the assessment of pain when standing. The change in this pain assessment before and after application of the patch was 40.9 mm for the TT-063 group and 30.6 mm for the FP group. As a result, the TT-063 group demonstrated significantly superior efficacy relative to the FP group. In other areas, the TT-063 group demonstrated clinically higher efficacy in terms of the assessment of pain when walking (VAS) and clinical symptoms, compared with the FP group. As a long-term trial, the clinical trials investigated the continuous application of TT-063 for 52 weeks, targeting 201 patients with osteoarthritis. The trials showed that 80% of the patients were able to continuously apply TT-063 over the trial period. Therefore, TT-063 was confirmed to possess good tolerability even during long-term use.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|